DOCSLIB.ORG

• at the Conclusion of This Program the Attendee Will: –Differentiate Lipid Management from Cardiovascular Risk Reduction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
• at the Conclusion of This Program the Attendee Will: –Differentiate Lipid Management from Cardiovascular Risk Reduction Lipid Assessment and Management: Analzye and Apply Current Guidelines from the USPS Task Force and ACCF/AHA Sally K. Miller, PhD, APN, FNP-BC, FAANP Associate Professor University of Nevada Las Vegas School of Nursing Nurse Practitioner Correct Care Solutions iCarePsychiatry Las Vegas, NV 1 Disclosures • I have no financial affiliations to disclose Objectives • At the conclusion of this program the attendee will: –Differentiate lipid management from cardiovascular risk reduction 3 Objectives –Analyze current guidelines for primary and secondary cardiovascular risk reduction –Analyze the mechanism of action of drugs for ASCVD risk reduction and lipid lowering –Apply pharmacotherpeutic principles in case studies 4 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol 5 What’s Different? • No clear value to adding additional drug classes for LDL reduction • LDL reduction is either “high intensity” or “moderate intensity” – no goal numbers 6 What’s Different? • Generally speaking, the other classes of lipid-lowering agents do not offer a benefit worth the cost, risk of adverse effects, and risk of statin-related interaction 7 No Role in ASCVD Risk Reduction • Niacin • Bile acid sequestrants • Fibric acid derivatives • Fish oil ** Some of these medications may have a role in other lipid disorders, e.g., hypertriglyceridemia 8 Statins are Categorized According to % LDL reduction • High intensity – > 50% reduction –Atorvastatin 40-80 mg daily –Rosuvastatin 20-40 mg daily 9 • Medium intensity – 30-49% reduction –Atorvastatin 10-20 mg daily –Rosuvastatin 10-20 mg daily –Simvastatin 20-40 mg daily –Pravastatin 40-80 mg daily –Lovastatin 40 mg daily 10 • No role for low intensity -- < 30% reduction –Pravastatin 10-20 mg daily –Lovastatin 20 mg daily 11 Four Statin Treatment Groups • Candidates for statin therapy are divided among four treatment groups 12 Statin Treatment Group #1 • Anyone over 21 – 75 years old with ASCVD –High intensity statin • Anyone > 75 year old or not a candidate for high intensity statin –Moderate intensity statin 13 Statin Treatment Group #2 • Any patient who has an LDL of > 190 mg/dL –No caveats according to age 14 Statin Treatment Group #3 • Patients between the ages of 40 – 75 years with type 1 or 2 diabetes mellitus –Moderate intensity therapy • This patient group with a 10 year ASCVD risk > 7.5% –High intensity statin 15 Statin Treatment Group #4 • Anyone 40-75 years old with a 10-year pooled risk for ASCVD > 7.5% –Moderate to high intensity statin therapy 16 Calculating Pooled Risk 17 USPS Task Force Recommendations Statin Use for Primary Prevention • Adults 40-75 years with no hx of CVD, 1 or more risk actors, and a 10 year risk > 10% –Low to moderate intensity statin –Level B recommendation 18 USPS Task Force Recommendations Statin Use for Primary Prevention • Adults 40-75 years with no hx of CVD, 1 or more risk actors, and a 10 year risk 7.5 to 10% –Consider low to moderate intensity statin –Benefit not as clear due to lower probability of disease –Level C recommendation 19 USPS Task Force Recommendations Statin Use for Primary Prevention • Insufficient evidence to assess the benefits and harms of initiating statins for primary prevention in patients 76 years of age and older without a hx of CVD 20 Case Study W.R. • W.R. is a 46-year-old Black male who presents for his annual wellness exam. • He denies any complaints – he is taking HCTZ for a diagnosis of HTN and feels well 21 W.R. • W.R.’s ROS is negative; he offers no complaints at all and is only here because he needs refills on his HCTZ 22 W.R. • Vital signs as follows: –Ht 70” Wt 235 lbs –98.5o F, 86 b.p.m., RR 18, 130/84 mm Hg • Physical exam is unremarkable 23 W.R. • Fractionated lipid profile as follows: –TC 266 mg/dL –HDL 67 mg/dL –LDL 168 mg/dL –TG 235 mg/dL 24 W.R. • Does W.R. need statin therapy? –Does he have existing ASCVD? –Does he have an LDL > 190 mg/dL? –Does he have type 1 or 2 DM? –Is his ASCVD 10 year risk > 7.5%? 25 W.R. 10 Year ASCVD Risk •Gender: Male • Age: 46 years old • Race: Black • TC: 266 mg/dL • HDL: 67 mg/dL • Sys BP: 130 mm Hg •Txfor HTN? Yes •DM? No •Smoker? No 26 K.G. • K.G. is a 42 year-old female who presents for an occupational biometrics examination • She denies any significant medical history and takes no daily medications 27 K.G. • K.G. denies any surgical history • K.G.’s social history includes –Married for 16 years, no children –1-2 drinks socially per month –1 pack of cigarettes daily for 20 years 28 K.G. • K.G.’s ROS is significant for: –Irregular menses –Occasional fatigue –Bilateral knee pain – Thinning hair 29 K.G. • Vital signs are as follows: –Ht 65” Wt 125 lbs –97.4o F, 62 b.p.m., RR 14, 134/78 mm Hg • Physical exam is unremarkable 30 K.G. • Fractionated lipid profile as follows: –TC 239 mg/dL –HDL 40 mg/dL –LDL 149 mg/dL –TG 201 mg/dL 31 K.G. • Does K.G. need statin therapy? –Does she have existing ASCVD? –Does she have an LDL > 190 mg/dL? –Does she have type 1 or 2 DM? –Is her ASCVD 10 year risk > 7.5%? 32 W.R. 10 Year ASCVD Risk •Gender: Female • Age: 42 years old • Race: Non-black • TC: 239 mg/dL • HDL: 40 mg/dL • Sys BP: 134 mm Hg •Txfor HTN? No •DM? No •Smoker? Yes 33 Benefits of Statins Beyond LDL Reduction • Pleotropic effects are uncertain at best –Improved endothelial cell function –Halting atheroma development –Reduced inflammation –Antithrombotic effects 34 The Very High Risk Patient • Guidelines are used to frame assessment and management decision in the majority of patients • There remain a group of very high risk patients who fall outside of standard guidelines 35 PCSK9 Inhibitors • The newest class of lipid lowering agent • Indicated for patients with – Heterozygous or homozygous familial hyperlipidemia who are tolerating maximal statin doses – Clinical ASCVD who need additional LDL lowering after maximal statin therapy PCSK9 Inhibitors • Under normal circumstances hepatic LDL receptors bind LDL and remove it from circulation – When the receptor returns to function, naturally occurring PCSK9 binds (blocks) it and interferes with further LDL receptor functioning – Because PCSK9 and LDL are dynamic physiologic processes, statins can actually increase PCSK9 activity PCSK9 Inhibitors • These medications block the naturally occurring protein PCSK9 that binds to LDL receptors on hepatocytes • By using this class of medication to block this protein, we block the degradation of LDL receptors • LDL receptors stay expressed on hepatocytes, and continue to facilitate removal of LDL from circulation PCSK9 Inhibitors • Generally LDL reduction is appreciated in the 50% range • This class of medication is currently not indicated for those who are intolerant of statins • At this point there are no data to support reduced cardiovascular events PCSK9 inhibitors • Very expensive – between $13,000 and $14,000 annually • Currently two are approved –Alirocumab (Praluent) –Evolocumab (Repatha) • Bococizumab is in phase III trials PCSK9 Inhibitors • Serious adverse events have not been a big issue – There have been hypersensitivity reactions – Most common adverse events – URI type symptoms –Back pain – Injection site reactions Remember… • Most FNPs will not be managing lipid abnormalities – you will be managing ASCVD risk with statins • Non-statin lipid medications are used for patients with familial or other mixed lipid abnormalities • At this point, patients requiring PCSK9 inhibitor will likely have this initiated by cardiology Other Medications Not Used for ASCVD Risk Reduction May be used in the management of other forms of dyslipidemia 43 Bile Acid Sequestrants – Cholestyramine, Colestipol, WelChol • Mechanism of action –Binds bile acids in the gut, interrupting reabsorption –More bile acids must be synthesized in the liver –LDL receptors on hepatocytes are increased 44 Bile Acid Sequestrants – Cholestyramine, Colestipol, Welchol •Dosing –WelChol in 625 mg tabs –Should be taken before meals 45 Bile Acid Sequestrants – Cholestyramine, Colestipol, Welchol • Side effects –Constipation –GI irritation or bleeding –LFT abnormalities –Complete bile duct obstruction –Hypertriglyceridemia 46 Bile Acid Sequestrants – Cholestyramine, Colestipol, Welchol • Side effects (cont.) –Drug interactions •Interferes with absorption of fat soluble vitamins •Interferes with absorption of oral anticoagulants, digoxin, penicillins, thyroid hormone, tetracyclines, iron salts 47 Fibric Acid Derivatives • Mechanism of action – Gemfibrozil (Lopid), fenofibrate (Tricor) and fenofibric acid (Trilipix)* – Increase activity of lipoprotein lipase, promoting catabolism of VLDL and triacylglycerols – Blocks lipolysis of triacylglycerols stored in adipose tissue – Not routinely indicated for coadministration with statins; if truly necessary, only Trilipix is indicated 48 Fibric Acid Derivatives • Mechanism of action –Stimulate endothelial receptor production of LPL –Significant reduction of triacylglycerol 49 Fibric Acid Derivatives • Adverse effects –Cholelithiasis –Dyspepsia, diarrhea –Myositis –LFT abnormalities –Headache, dizziness –Impotence 50 Fibric Acid Derivatives • Laboratory evaluation –Liver and renal function tests at start of therapy –May decrease serum glucose –May decrease serum uric acid 51 Cholesterol Absorption Inhibitor • Only one in class - ezetimibe • Mechanism of action –Complexes with bile salts and blocks absorption of cholesterol from very precise absorption sites in the duodenum 52 Cholesterol Absorption Inhibitor • Mechanism of action – Decreased absorption from the gut leads to decreased cholesterol stores in the hepatic free cholesterol pool – Resulting upregulation of LDL-C receptors increases plasma clearance of LDL by up to an additional 25% 53 Cholesterol Absorption Inhibitor • When given with an HMG-CoA reductase inhibitor –May increase risk of myositis and other statin-related effects –Should not be given in moderate to severe hepatic insufficiency 54 References • American College of Cardiology/American Heart Association Task Force. (2014).
Load more

Recommended publications
  • Us 2018 / 0296525 A1
    UN US 20180296525A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0296525 A1 ROIZMAN et al. ( 43 ) Pub . Date: Oct. 18 , 2018 ( 54 ) TREATMENT OF AGE - RELATED MACULAR A61K 38 /1709 ( 2013 .01 ) ; A61K 38 / 1866 DEGENERATION AND OTHER EYE (2013 . 01 ) ; A61K 31/ 40 ( 2013 .01 ) DISEASES WITH ONE OR MORE THERAPEUTIC AGENTS (71 ) Applicant: MacRegen , Inc ., San Jose , CA (US ) (57 ) ABSTRACT ( 72 ) Inventors : Keith ROIZMAN , San Jose , CA (US ) ; The present disclosure provides therapeutic agents for the Martin RUDOLF , Luebeck (DE ) treatment of age - related macular degeneration ( AMD ) and other eye disorders. One or more therapeutic agents can be (21 ) Appl. No .: 15 /910 , 992 used to treat any stages ( including the early , intermediate ( 22 ) Filed : Mar. 2 , 2018 and advance stages ) of AMD , and any phenotypes of AMD , including geographic atrophy ( including non -central GA and Related U . S . Application Data central GA ) and neovascularization ( including types 1 , 2 and 3 NV ) . In certain embodiments , an anti - dyslipidemic agent ( 60 ) Provisional application No . 62/ 467 ,073 , filed on Mar . ( e . g . , an apolipoprotein mimetic and / or a statin ) is used 3 , 2017 . alone to treat or slow the progression of atrophic AMD Publication Classification ( including early AMD and intermediate AMD ) , and / or to (51 ) Int. CI. prevent or delay the onset of AMD , advanced AMD and /or A61K 31/ 366 ( 2006 . 01 ) neovascular AMD . In further embodiments , two or more A61P 27 /02 ( 2006 .01 ) therapeutic agents ( e . g ., any combinations of an anti - dys A61K 9 / 00 ( 2006 . 01 ) lipidemic agent, an antioxidant, an anti- inflammatory agent, A61K 31 / 40 ( 2006 .01 ) a complement inhibitor, a neuroprotector and an anti - angio A61K 45 / 06 ( 2006 .01 ) genic agent ) that target multiple underlying factors of AMD A61K 38 / 17 ( 2006 .01 ) ( e .
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • PCSK9 Inhibitors – Clinical Applications
    VOLUME 39 : NUMBER 5 : OCTOBER 2016 EXPERIMENTAL AND CLINICAL PHARMACOLOGY PCSK9 inhibitors – clinical applications Robert Schmidli Consultant endocrinologist SUMMARY Department of Endocrinology The enzyme PCSK9 has an important role in regulating low-density lipoprotein (LDL) receptors Canberra Hospital and concentrations of LDL cholesterol. Inhibiting this enzyme could therefore reduce the incidence of ischaemic heart disease. Keywords The monoclonal antibodies alirocumab, evolocumab and bococizumab are directed against alirocumab, bococizumab, PCSK9 and inhibit its activity. Phase II trials have shown alirocumab and evolocumab to be evolocumab, ischaemic heart disease, LDL effective at lowering LDL cholesterol. cholesterol, proprotein Preliminary results of these phase II trials show potential benefits in ischaemic heart disease. convertase subtilisin/kexin type 9 Reports of adverse effects, including muscular symptoms and neurocognitive changes, were low. Large phase III cardiovascular outcome trials of these monoclonal antibodies will determine their Aust Prescr 2016;39:168–70 safety and efficacy. These drugs may have a role in the management of patients at very high risk http://dx.doi.org/10.18773/ of cardiovascular events such as those with familial hypercholesterolaemia. austprescr.2016.061 Introduction PCSK9 inhibitory antibodies The incidence of deaths from ischaemic heart disease Studies of uncommon mutations, such in Australia has reduced since the 1960s. While about as the LDL‑receptor mutations in familial half of this reduction is due to interventions such as hypercholesterolaemia, have led to important coronary revascularisation and secondary prevention, therapeutic advances in the study of lipids and the remainder is due to addressing risk factors such as cardiovascular disease. Proprotein convertase smoking, lipids and hypertension.
    [Show full text]
  • A61p1/16 (2006.01) A61p3/00 (2006.01) Km, Ml, Mr, Ne, Sn, Td, Tg)
    ( (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, A61P1/16 (2006.01) A61P3/00 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 31/192 (2006.01) C07C 321/28 (2006.01) Declarations under Rule 4.17: (21) International Application Number: — as to the applicant's entitlement to claim the priority of the PCT/IB2020/000808 earlier application (Rule 4.17(iii)) (22) International Filing Date: Published: 25 September 2020 (25.09.2020) — with international search report (Art. 21(3)) (25) Filing Language: English — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (26) Publication Language: English amendments (Rule 48.2(h)) (30) Priority Data: 62/906,288 26 September 2019 (26.09.2019) US (71) Applicant: ABIONYX PHARMA SA [FR/FR] ; 33-43 Av¬ enue Georges Pompidou, Batiment D, 31130 Bahna (FR). (72) Inventor: DASSEUX, Jean-Louis, Henri; 7 Allees Charles Malpel, Bat. B, 31300 Toulouse (FR). (74) Agent: HOFFMANN EITLE PATENT- UND RECHTSANWALTE PARTMBB, ASSOCIATION NO. 151; Arabellastrasse 30, 81925 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
    [Show full text]
  • Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
    Journal of Personalized Medicine Review Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia Nagham N. Hindi 1,†, Jamil Alenbawi 1,† and Georges Nemer 1,2,* 1 Division of Genomics and Translational Biomedicine, College of Health and Life Sciences, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar; [email protected] (N.N.H.); [email protected] (J.A.) 2 Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut DTS-434, Lebanon * Correspondence: [email protected]; Tel.: +974-445-41330 † Those authors contributed equally to the work. Abstract: The exponential expansion of genomic data coupled with the lack of appropriate clinical categorization of the variants is posing a major challenge to conventional medications for many common and rare diseases. To narrow this gap and achieve the goals of personalized medicine, a collaborative effort should be made to characterize the genomic variants functionally and clinically with a massive global genomic sequencing of “healthy” subjects from several ethnicities. Familial- based clustered diseases with homogenous genetic backgrounds are amongst the most beneficial tools to help address this challenge. This review will discuss the diagnosis, management, and clinical monitoring of familial hypercholesterolemia patients from a wide angle to cover both the genetic mutations underlying the phenotype, and the pharmacogenomic traits unveiled by the conventional and novel therapeutic approaches. Achieving a drug-related interactive genomic map will potentially benefit populations at risk across the globe who suffer from dyslipidemia. Citation: Hindi, N.N.; Alenbawi, J.; Nemer, G. Pharmacogenomics Variability of Lipid-Lowering Keywords: familial hypercholesterolemia; pharmacogenomics; PCSK9 inhibitors; statins; ezetimibe; Therapies in Familial novel lipid-lowering therapy Hypercholesterolemia.
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?
    Journal of Clinical Medicine Review Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible? Pier Luigi Temporelli 1,*, Marcello Arca 2, Laura D’Erasmo 2 and Raffaele De Caterina 3,4 1 Division of Cardiology, Istituti Clinici Scientifici Maugeri, IRCCS, Via Revislate 13, 28013 Gattico-Veruno, Italy 2 Department of Translational and Precision Medicine, Sapienza University of Rome, Viale dell’Università 37, 00161 Roma, Italy; [email protected] (M.A.); [email protected] (L.D.) 3 Chair of Cardiology, Cardiovascular Division, Pisa University Hospital, University of Pisa, Via Paradisa 2, 56126 Pisa, Italy; [email protected] 4 Fondazione Villa Serena per la Ricerca, 65013 Città Sant’Angelo, Italy * Correspondence: [email protected]; Tel.: +39-0322-884711 Abstract: Hyperlipidemia is a powerful risk factor for coronary heart disease (CHD). It has been known for a long time that lipid-lowering drugs significantly reduce morbidity from CHD, thus proving a causal role for cholesterol in coronary events. Conversely, the relationship between low- density lipoprotein cholesterol (LDL-C) levels and stroke has been less clear and debated for many years. Recent data conclusively demonstrate not only the inverse epidemiological relationship of blood LDL-C with stroke, but also the efficacy of different strategies to attain cholesterol-lowering on stroke. They also dissipate lingering doubts about the possibility that lipid-lowering is linked to an increase in hemorrhagic stroke. However, despite current international lipid guidelines now strongly recommend aggressive lipid-lowering therapy in patients with atherosclerotic cardiovascular disease, including CHD and cerebrovascular disease (CeVD), secondary prevention patients are often undertreated with lipid-lowering therapies in routine clinical practice.
    [Show full text]
  • Articles Article: Non-Statin Treatments for Managing LDL Cholesterol and Their Outcomes Download
    Clinical Therapeutics/Volume 37, Number 12, 2015 Review Article Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes Traci Turner, MD; and Evan A. Stein, MD, PhD Metabolic & Atherosclerosis Research Center, Cincinnati, Ohio ABSTRACT agents are being developed as orphan indications ex- Purpose: Over the past 3 decades reducing LDL-C pressly for patients with homozygous familial hyper- has proven to be the most reliable and easily achiev- cholesterolemia, including peroxisome proliferator able modifiable risk factor to decrease the rate of activated receptor-δ agonists, angiopoietin-like protein 3 cardiovascular morbidity and mortality. Statins are inhibitors, and gene therapy. effective, but problems with their side effects, adher- Implications: Monoclonal antibodies that inhibit ence, or LDL-C efficacy in some patient groups PCSK9 were shown to be very effective reducers of remain. Most currently available alternative lipid- LDL-C and well tolerated despite subcutaneous ad- modifying therapies have limited efficacy or tolerabil- ministration, and no significant safety issues have yet ity, and additional effective pharmacologic modalities emerged during large Phase II and III trials. They have to reduce LDL-C are needed. the potential to substantially impact further the risk of Methods: Recent literature on new and evolving cardiovascular disease. A number of additional new, LDL-C–lowering modalities in preclinical and clinical but less effective, oral LDL-C–lowering agents are development was reviewed. also in various stages of development, including Findings: Several new therapies targeting LDL-C are some which are targeted only to patients with homo- in development. Inhibition of proprotein convertase sub- zygous familial hypercholesterolemia. (Clin Ther.
    [Show full text]
  • Multi-Country Non-Interventional Study on the Effectiveness and Safety of Empagliflozin in Adult Patients with Type 2 Diabetes in Europe and Asia
    ABCD e title PAGE Protocol for non-interventional studies based on existing data TITLE PAGE Document Number: c26457869-02 BI Study Number: 1245.195 BI Investigational Jardiance ® (empagliflozin) Product(s): Title: Multi-country non-interventional study on the effectiveness and safety of Empagliflozin in adult patients with type 2 diabetes in Europe and Asia Protocol version 2.0 identifier: Date of the last version 29 November 2018 of the protocol: PASS: No EU PAS register EUPAS27606 number: Active substance: A10BK03 empagliflozin Medicinal product: Jardiance Product reference: Europe: EMEA/H/C/002677 Asia: NA Procedure number: N/A Joint PASS: No Research question and The main objective of this study is to compare effectiveness objectives: outcomes between the incident users of empagliflozin or any SGLT-2 inhibitor and the incident users of any DPP-4 inhibitor. The effectiveness outcomes include, where available, cardiovascular events, renal effectiveness outcomes, and cardiovascular and all-cause mortality. Additional analyses include safety outcomes. Health care resources utilization and cost of care outcomes will also be evaluated. Countries of study: Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan, United Kingdom. Other countries may be included later. 001-MCS-90-124_RD-01 (4.0) Boehringer Ingelheim Page 2 of 132 Protocol for non-interventional studies based on existing data BI Study Number 1245.195 c26457869-02 Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies Author: StatFinn-EPID Research: Ilkka Tamminen, Katja Hakkarainen, Fabian Hoti, Riho Klement, Juha Mehtälä, Laura Saarelainen, Giorgi Tskhvarashvili Harvard Medical School: Elisabetta Patorno, MD, PhD Boehringer Ingelheim: Anouk Déruaz Luyet, PhD Kimberly G.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Perspectives in Lipid Lowering Therapy. New Therapies Targeting Ldl – Cholesterol
    FARMACIA, 2018, Vol. 66, 1 REVIEW PERSPECTIVES IN LIPID LOWERING THERAPY. NEW THERAPIES TARGETING LDL – CHOLESTEROL 1,2 2 1,2 ADRIANA MIHAELA ILIEŞIU *, IRINA PÂRVU , ANDREEA SIMONA HODOROGEA , IOAN TIBERIU NANEA 1,2, ANDREEA CATARINA POPESCU 1 1“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania 2“Prof. Dr. Th. Burghele” Clinical Hospital, Department of Internal Medicine and Cardiology, 20 Panduri Road, District 5, Bucharest, Romania *corresponding author: [email protected] Manuscript received: May 2017 Abstract New lipid-lowering drugs are needed, because current treatment options, in which statins play a central role, are limited by suboptimal control of low-density lipoprotein cholesterol (LDL-C), the ineffectiveness of treatment in some forms of dyslipidaemia, and residual cardiovascular risks. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, among which human monoclonal antibodies are currently recommended by guidelines, increase the number of LDL receptors, lowering serum LDL-C levels. Monoclonal antibodies are indicated, in addition to diet and statins in highest tolerated doses, in heterozygous familial hypercholesterolemia, or in patients with high cardiovascular risk, when a lower level of LDL-C is required. Bempedoic acid (ETC 1002) is an inhibitor of adenosine triphosphate citrate lyase, reducing cholesterol synthesis in hepatocytes, with hypocholesterolemic and anti-inflammatory effects. In familial hypercholesterolemia, apoB-100 inhibitors (the antisense oligonucleotide mipomersen) or
    [Show full text]
  • Bococizumab for Primary Hyperlipidaemia and Mixed Dyslipidaemia – Adjunctive to Statin Therapy And/Or Diet
    October Horizon Scanning Research & 2016 Intelligence Centre Bococizumab for primary hyperlipidaemia and mixed dyslipidaemia – adjunctive to statin therapy and/or diet NIHR HSRIC ID: 6837 Lay summary Bococizumab is a new drug to treat high levels of fat and cholesterol in the bloodstream (primary hyperlipidemia and mixed dyslipidemia). These conditions can cause a build-up of fatty deposits (plaques) in the arteries, which may lead to heart attacks and strokes. Bococizumab is given by subcutaneous injection. Some studies have suggested that this drug in combination with other cholesterol lowering drugs may help to reduce the risk of heart attacks and strokes. This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. Horizon Scanning Research & Intelligence Centre University of Birmingham [email protected] www.hsric.nihr.ac.uk @OfficialNHSC TARGET GROUPS • Primary hyperlipidaemia: heterozygous familial and non-familial – adjunctive to diet; in combination with statin. • Mixed dyslipidaemia – adjunctive to diet; in combination with statin. • Primary hyperlipidaemia or mixed dyslipidaemia: statin-intolerant, or patients in whom statins are contraindicated – adjunctive to diet. TECHNOLOGY DESCRIPTION Bococizumab (PF-04950615; RN316) is one of a new class of lipid regulating drugs, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    [Show full text]